Prostate
cancer Prolonging overall survival in
progressive CRPC
Alan So, MD, FRCSC, Associate Professor,
Department of Urologic Sciences, University of British Columbia;
Research Scientist, Prostate Centre, Vancouver General Hospital.
To view the complete article click
here (pdf format)
TRIAL SUMMARY: MDV3100 improves
overall survival in men with CRPC post chemotherapy
To view the complete article click
here (pdf format)
ANNUAL MEETING OF ASCO GU CANCERS SYMPOSIUM February 2-4, San Francisco,
California
In Brief
Already known
MDV3100, through binding to the androgen
receptor (AR), prevents AR activation and inhibits both AR nuclear
translocation and association of the AR with DNA.
MDV3100 showed activity in prostate cancer
model systems with overexpressed AR and in a Phase I–II trial
enrolling pre- and postchemotherapy-treated patients with progressive
castration-resistant prostate cancer (CRPC).
What this study showed
In the AFFIRM trial, MDV3100 showed significant
benefits compared to placebo in terms of overall survival, time
to both PSA and radiographic progression, as well as PSA decline.
The drug was generally well tolerated.
Next steps
Results are awaited from the PREVAIL trial,
which is currently evaluating the use of MDV3100 in chemotherapy-
naive CRPC patients.
Questions remain about the optimal use
of several new agents available for CRPC.
